Table 3 Relative risk of second primary cancer by type of first primary cancer and follow-up period

Oral Cavity & Pharynx

(2.75–3.80)

(3.31–3.77)

(2.93–3.44)

(2.33–2.86)

Oesophagus

(1.06–2.49)

(2.06–2.97)

(1.35–2.59)

(1.79–3.84)

Stomach

(0.67–1.30)

(0.93–1.25)

(1.12–1.55)

(1.24–1.73)

Colorectal

(0.95–1.21)

(1.04–1.15)

(1.13–1.26)

(1.21–1.36)

Liver & Intrahepatic Bile Ducts

(0.62–1.89)

(0.85–1.52)

(1.03–2.52)

(1.40–4.87)

Pancreas

(0.40–1.33)

(0.78–1.52)

(0.56–2.05)

(0.66–3.06)

Larynx

(1.84–3.37)

(2.47–3.06)

(2.04–2.63)

(1.89–2.50)

Lung

(1.26–1.69)

(1.41–1.65)

(1.73–2.11)

(1.90–2.40)

Skin Melanoma

(1.03–1.52)

(1.04–1.21)

(1.13–1.32)

(1.22–1.41)

Breast female

(0.67–0.90)

(0.80–0.89)

(0.96–1.06)

(1.08–1.19)

Cervix Uteri

(0.56–2.06)

(1.16–1.74)

(1.38–2.01)

(1.44–1.92)

Corpus Uteri & NOS

(0.65–1.25)

(1.03–1.27)

(1.00–1.24)

(1.25–1.49)

Ovary

(0.43–1.30)

(0.74–1.12)

(1.08–1.65)

(1.44–2.05)

Prostate

(0.61–0.76)

(0.68–0.74)

(0.72–0.79)

(0.85–0.97)

Testis

(0.10–3.00)

(1.17–2.03)

(0.99–1.67)

(1.17–1.56)

Kidney

(1.21–2.07)

(1.12–1.41)

(1.07–1.39)

(1.27–1.66)

Bladder

(1.47–2.06)

(1.32–1.54)

(1.30–1.56)

(1.46–1.78)

Brain & Central Nerves

(0.62–2.43)

(0.82–1.72)

(0.70–1.82)

(1.15–2.50)

Thyroid

(0.73–2.20)

(1.22–1.71)

(0.98–1.42)

(1.34–1.80)

Hodgkin Lymphoma

(0.21–2.85)

(2.28–3.49)

(1.56–2.62)

(2.30–3.26)

Non Hodgkin Lymphoma

(0.97–1.56)

(1.16–1.39)

(1.26–1.54)

(1.44–1.79)

Multiple Myeloma

(0.38–1.12)

(0.86–1.21)

(1.13–1.76)

(0.88–1.88)

Leukaemia

(0.80–1.48)

(1.29–1.58)

(1.49–1.88)

(1.57–2.08)

All Cancers

(1.06–1.15)

(1.09–1.13)

(1.15–1.19)

(1.34–1.39)